B16-BL6 melanoma cells release inhibitory factor(s) of active pump activity in isolated lymph vessels

We investigated whethersupernatant cultured with melanoma cell lines B16-BL6 and K1735 or theLewis lung carcinoma cell line (LLC) can regulate lymphatic pumpactivity with bioassay preparations isolated from murine iliac lymphvessels. B16-BL6 and LLC supernatants caused significantdilation of lymph microvessels with cessation of pump activity. B16-BL6supernatant produced dose-related cessation of lymphatic pump activity.There was no significant tachyphylaxis in the supernatant-mediatedinhibitory response of lymphatic pump activity. Pretreatment with3 × 10⁵ MN-nitro-L-arginine methyl ester(L-NAME) or 10⁷ M or 10⁶ Mglibenclamide and 5 × 10⁴ M 5-hydroxydecanoic acidcaused significant reduction of supernatant-mediated inhibitoryresponses. Simultaneous treatment with 10³ ML-arginine and 3 × 10⁵ ML-NAME significantly lessened L-NAME-inducedinhibition of the supernatant-mediated response, suggesting thatendogenous nitric oxide (NO) plays important roles insupernatant-mediated inhibitory responses. Chemical treatment dialyzedsubstances of <1,000 molecular weight (MW), producing completereduction of the supernatant-mediated response. In contrast,pretreatment with heating or digestion with protease had no significanteffect on supernatant-mediated response. These findings suggest thatB16-BL6 cells may release nonpeptide substance(s) of <1,000 MW,resulting in significant cessation of lymphatic pump activity viaproduction and release of endogenous NO and activation of mitochondrialATP-sensitive K⁺ channels.